Company: APACU
Filing Date: 2025-05-05
Form Type: S-1
Source: 0001829126-25-003414
Chunk: 127

Company: StoneBridge Acquisition II Corp
Filing Date: 2025-05-05
Form: S-1
Chunk 127
---
 not qualify as covered securities under the statute and we would be subject to regulation in each state in which we offer our securities.

Our sponsor paid an aggregate of $25,000, or approximately $0.01 per founder share and, accordingly, you will experience immediate and substantial dilution from the purchase of our Class A ordinary shares.

The difference between the public offering price
per share (allocating all of the unit purchase price to the Class A ordinary share and none to the right included in the unit) and the
pro forma net tangible book value per share of our Class A ordinary shares after this offering constitutes the dilution to you and the
other investors in this offering. Our sponsor acquired the founder shares at a nominal price, significantly contributing to this dilution.
Upon closing of this offering, and assuming no value is ascribed to the rights included in the units, you and the other public shareholders
will incur an immediate and substantial dilution of approximately 25% (or $2.50 per share, assuming no exercise of the underwriter’s
over-allotment option), the difference between the pro forma net tangible book value per share after this offering of $7.50 and the initial
offering price of $10.00 per unit. This dilution would increase to the extent that the anti-dilution provisions of the founder shares
result in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the founder shares at the time
of our initial business combination. In addition, because of the anti-dilution protection in the founder shares, any equity or equity-linked
securities issued in connection with our initial business combination would be disproportionately dilutive to our Class A ordinary shares.

The non-managing sponsor investors have expressed an interest to purchase units in this offering, which could reduce the trading volume, volatility and liquidity for our shares, adversely affecting the trading price of our shares.

The non-managing sponsor investors have expressed to us an interest in purchasing up to an aggregate of approximately units in this offering at the offering price (assuming the exercise in full of the underwriter’s over-allotment option). None of the non-managing sponsor investors has expressed to us an interest in purchasing more than 9.9% of the units to be sold in this offering. Because these expressions of interest are not binding agreements or commitments to purchase, each of the non-managing sponsor investors may determine to purchase fewer or no units in this offering or the underwriter may determine to sell fewer